Ossium Health: The Case for Rebuilding the Immune System From Scratch

In a four-patient clinical trial, all participants who received cryopreserved deceased-donor bone marrow from Ossium Health’s banked supply achieved full donor chimerism — meaning their blood-forming systems were completely replaced — and remained alive and relapse-free at Day 180 with no infusion-related toxicity and no cytokine release syndrome.

Why This Is More Than an Oncology Story

Bone marrow transplant has existed as a clinical tool for decades, confined almost entirely to hematologic malignancies as a last-resort salvage intervention. Ossium Health is building the infrastructure that would eventually allow it to function as something else — a preventive or rejuvenative intervention.

The company’s core innovation is a cryopreserved, off-the-shelf bone marrow bank sourced from deceased organ donors. No living matched donor is required. The primary bottleneck to bone marrow transplant at scale has always been donor availability and matching, not the procedure itself. A scalable supply of clinically viable banked marrow makes that access problem tractable for the first time.

The PRESERVE I Data and What It Shows

The PRESERVE I clinical trial (NCT05589896) enrolled four patients with hematologic malignancies. All four achieved rapid neutrophil engraftment and platelet recovery — the early engraftment signals that indicate the transplanted marrow is establishing itself. All four achieved full donor chimerism: the recipient’s hematopoietic (blood-forming) system was completely replaced by donor-derived cells, not partially. Immune reconstitution was successful across all evaluatable patients. There was no infusion-related toxicity, no cytokine release syndrome, and while acute graft-versus-host disease (GVHD) occurred and was managed with steroids, no chronic GVHD was observed. At Day 180, all evaluatable patients were alive and relapse-free.

These results were presented at the 2026 Tandem Meetings (February 4–7, 2026) and at ASH 2025. A peer-reviewed study published in Cytotherapy in January 2026 independently assessed Ossium’s production process and concluded that the marrow was “produced at scale with exceptional consistency, long-term stability, and strong clinical performance.” CEO Kevin Caldwell described the presentations as highlighting “the growing clinical body of evidence supporting the feasibility, safety, and transformative potential of Ossium bone marrow.”

Four patients is a small trial. Safety and feasibility data from PRESERVE I are promising, not definitive. The absence of a control arm, the highly selected patient population, and the 180-day follow-up window all limit what conclusions can be drawn. Larger trials will be required before any expansion of indication — including into preventive or longevity applications — becomes conceivable.

The Longevity Mechanism Behind the Research

The reason this research sits at the intersection of oncology and longevity biology is immunosenescence. With age, hematopoietic stem cell (HSC) function declines — HSCs are the progenitors of every immune cell type — and the downstream effects are measurable: reduced naive immune cell output, dysfunctional memory cell accumulation, and elevated inflammatory signaling from cytokines including IL-1β, TNF, IL-6, and TGF-β1. This contributes to both impaired immune defense and the chronic inflammation implicated in cardiovascular disease, neurodegeneration, and failed cancer immune surveillance.

Replacing aged HSCs with young donor-derived HSCs is a direct intervention on that mechanism — not a lifestyle protocol, but a structural reset of the immune cell production apparatus. Whether that reset is durable and beneficial outside the malignancy context requires substantially more evidence than currently exists.

For adjacent context on immune system monitoring and modeling approaches that are closer to current availability, see the Stack Archive coverage of immune digital twin platforms. On the fasting-mediated regenerative approaches that operate on overlapping mechanisms, see Fasting as Regenerative Medicine.

Source: Longevity Technology

Content created with AI assistance and reviewed for accuracy.